FindTrial
Sign In

Classification of risk groups of prostate cancer patients by using radiomics features in PSMA PET/CT images, which is done through a machine learning approach.

PSMA PET radiomics for prostate cancer risk stratification; a machine learning approach

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055109
Enrollment
100
Registered
2023-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C61- Malignant neoplasm of prostate

Interventions

None listed

Sponsors

Dept of nuclear medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients with age >= 18 years 2)Biopsy proven prostate cancer 3)Biopsies performed at least 4 weeks prior to 68Ga-PSMA-11 PET/CT, or after 68Ga-PSMA PET/CT

Exclusion criteria

Exclusion criteria: 1)Patients without pathological confirmation of prostate cancer 2)Patients who have received prior treatment or are receiving any form of treatment 3)Patients with no PSA assay 4)History of allergy to components of 68Ga-PSMA-11 or compounds of similar chemical characteristics 5)Patients with other known malignancies, both active and treated 6)Refusal to give informed written consent (for patients enrolled prospectively)

Design outcomes

Primary

MeasureTime frame
Predicting NCCN risk groups in prostate cancer using PSMA PET radiomicsTimepoint: At 2 years—

Secondary

MeasureTime frame
Predicting ISUP grades in prostate cancer using PSMA PET radiomicsTimepoint: At 2 years—

Countries

India

Contacts

Public ContactDr Kavin M

AIIMS New delhi

drbkimc_k@aiims.edu8472950769

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026